D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Dominick Colangelo, President and CEO of Vericel Corp (NASDAQ:VCEL), a $2.27 billion market cap company currently trading near InvestingPro’s Fair Value estimate, recently executed significant transactions involving the company’s stock. On March 12 and 13, Colangelo sold a total of 53,183 shares of common stock, yielding approximately $2.45 million. The shares were sold at prices ranging from $45.78 to $46.31 per share.
In addition to these sales, Colangelo exercised stock options to acquire 53,183 shares at a price of $1.95 per share, which were then sold as part of the aforementioned transactions. Following these activities, Colangelo holds 259,997 shares of Vericel Corp. The sales were conducted under an automatic trading plan established in December 2024. According to InvestingPro, the company maintains strong financial health with a 4.23x current ratio and has delivered impressive five-year returns. Discover 15 additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Vericel Corporation reported strong financial results for the fourth quarter of 2024, with a notable 20% year-over-year increase in total revenue, reaching $237.2 million. The company’s net income turned positive, achieving $10.4 million compared to a loss of $3.2 million in the previous year. Vericel’s gross margin for the quarter reached a record 78%, contributing to a full-year gross margin of 73%. The company has also provided optimistic guidance for 2025, projecting revenue growth of 20-23% and maintaining a gross margin of 73-74%.
Additionally, Truist Securities has revised its price target for Vericel to $61 from $67, while maintaining a Buy rating, reflecting confidence in the company’s growth potential despite a slight adjustment in expectations. This adjustment follows Vericel’s financial updates, which included a shortfall in Epicel revenue but stronger performance from MACI. Analysts at Truist view the company’s full-year 2025 guidance as conservative, anticipating increased sales following the launch of MACI Arthro and other products in the pipeline.
Vericel’s strategic initiatives, including the expansion of its MACI and burn care franchises, have positioned it for sustained growth. The company’s management emphasized the strong early indicators for MACI Arthro adoption and plans for international market entry in the coming years. The company also expects continued high revenue and profitability growth as it moves into 2025 and beyond.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.